Detailed Canine Results Qualified Broad Cannabis Respiratory and Blood-Pressure Nulls

Although the canine cannabis paper broadly described respiratory function and blood pressure as largely unaffected, its detailed results included isolated significant comparisons. A summary of mostly null findings should preserve those exceptions.

The respiratory measures did not all agree

Respiratory rate and tidal volume did not show significant changes under the reported conditions. The results nevertheless describe reduced minute volume with THC at one cumulative dose compared with baseline. The absence of a significant respiratory-rate change is therefore not equivalent to a null result for every breathing measure.

Blood pressure had a specific exception as well

The paper reports increased mean blood pressure with the THC–CBD combination at the highest cumulative dose relative to baseline. Other pressure changes were described largely as nonsignificant trends. These findings should not be collapsed either into no pressure effect anywhere or into a uniform hypertensive response.

The evidence is acute and exploratory

Six male Beagles underwent several measurements across escalating exposures. Isolated significant findings warrant precise reporting, while their reproducibility and clinical importance need separate evidence. The trial does not establish a human respiratory-risk threshold, and statistical nonsignificance elsewhere does not demonstrate exact equivalence. The defensible account is that most respiratory and pressure measures were unchanged, with named exceptions in the detailed results. This preserves the main pattern without allowing a broad abstract statement to erase narrower observations in the body of the paper.

Related analysis: the canine study’s separate physiological outcomes.

Research cited

Rutjanavate, Dong and Sawangkoon. Cumulative Effects of Cannabis Oils on Body Temperature, Electrocardiography, Heart Rate Variability, Blood Pressure, and Respiratory Function in Telemetered Dogs. DOI: 10.4103/IJVSM.IJVSM_3_25.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Rheumatoid-Arthritis Cannabis-Spray Trial Measured Pain Relief Rather Than Joint Protection

A small rheumatoid-arthritis trial summarized in a nabiximols review found improvement in selected pain outcomes. Those symptom findings did not establish that the spray prevented joint damage or replaced disease-modifying treatment. The trial tested a standardized combination The placebo-controlled study involved 58 patients treated for five weeks with THC:CBD oromucosal…

Spread the love

Read Article: A Rheumatoid-Arthritis Cannabis-Spray Trial Measured Pain Relief Rather Than Joint Protection

Responder Findings in a Small Nabiximols Chemotherapy-Pain Pilot Remained Exploratory

A small crossover pilot of nabiximols for chemotherapy-induced neuropathic pain did not show a significant average treatment effect, although a responder analysis identified some patients with meaningful relief. That pattern supports a research lead rather than a validated way to select responders. The average comparison was not positive The review’s…

Spread the love

Read Article: Responder Findings in a Small Nabiximols Chemotherapy-Pain Pilot Remained Exploratory

A Nabiximols Spinal-Cord-Injury Trial Found Similar Pain Changes With Spray and Placebo

A trial of THC:CBD spray for spinal-cord-injury neuropathic pain reported nearly identical average pain changes with active treatment and placebo. Improvement from baseline alone did not demonstrate an added spray benefit. The comparison concerned a defined pain population The review summarizes a randomized study registered as NCT01606202. Its evidence table…

Spread the love

Read Article: A Nabiximols Spinal-Cord-Injury Trial Found Similar Pain Changes With Spray and Placebo

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us